FDA: Cyramza Approval Now Includes Non-Small-Cell Lung CA
First approved in April to treat advanced cancers of the stomach or gastrointestinal tract
FRIDAY, Dec. 12, 2014 (HealthDay News) -- U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.
Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs.
Cyramza was first approved in April to treat advanced stomach cancer or gastroesophageal junction (GEJ) adenocarcinoma, and approval was widened in November to include advanced gastric or GEJ adenocarcinoma in combination with paclitaxel.
Clinical side effects have included neutropenia, stomatitis, fatigue, severe bleeding, blood clots, raised blood pressure, and impaired wound healing.
Cyramza is marketed by Eli Lilly, based in Indianapolis.